SPDR S&P Biotech ETF ETF Prediction and Forecast [XBI]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 06 Sept 2025, 03:57 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for SPDR S&P Biotech ETF ETF Prediction and Forecast [XBI]](https://i.ytimg.com/vi/OOL2-9ZIOeY/hqdefault.jpg)
AI-generated source summary
The video provides a technical analysis of the SPDR S&P Biotech ETF (XBI). Since August 12, 2025, the system ranked the ETF as hold or accumulate, with a score of 0. The ETF has gained nearly 10% since the initial recommendation, yielding an average return of 0.55% per day. The exchange-traded fund has broken through a strong upward trend. There is potential support at $94.01. According to fan theory, $100.33 is the next potential peak. The current 3-month trend indicates a potential 10.24% change, with a projected return ranging from 1.26% to 8.56%. A 12-month analysis indicates a projected change of -15.46%, with a potential range of -$44.59 to -$15.46. A stop-loss is set at $91.79. A general buy signal exist, however the open price are overvalued. This assessment has several positive signals but are downgraded.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.